The efforts of Mutual Pharmaceutical Company Inc. to price its gout drug Colcrys (colchicine) on a different level from unapproved products has drawn political criticism, and now the firm’s efforts to clinically differentiate the drug have drawn a regulatory critique for omitting and minimizing risk information.
FDA is asking Mutual to stop using two promotional pieces, one a pharmacy sell sheet with a photo of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?